<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638790</url>
  </required_header>
  <id_info>
    <org_study_id>HL-Russia-1</org_study_id>
    <nct_id>NCT04638790</nct_id>
  </id_info>
  <brief_title>First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)</brief_title>
  <acronym>HL-Russia-1</acronym>
  <official_title>First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The&#xD;
      primary objective is to assess efficacy, safety and progression-free survival (PFS) of&#xD;
      different approaches (earle favorable, early unfavorable and advanced stages) to first line&#xD;
      chemotherapy for classical Hodgkin Lymphoma (HL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is devoted to patients affected with Hodgkin Lymphoma in Russia.&#xD;
&#xD;
      The study aims to assess the efficacy and safety of three different approaches to first line&#xD;
      chemotherapy for classical Hodgkin Lymphoma (HL):&#xD;
&#xD;
        1. Early favourable (stages I-IIA without unfavorable risk factors). Patients will receive&#xD;
           two courses of standard ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine).&#xD;
           Those with a PET-2 (positron emission tomography) negative scan (Deauville Score 1-3)&#xD;
           will proceed with radiotherapy on initially involved site (20 Gy). Those with a PET-2&#xD;
           Deauville score 4 will proceed with additional 2 ABVD courses. After that, those with a&#xD;
           PET-4 negative scan (Deauville Score 1-3) will proceed with radiotherapy on initially&#xD;
           involved site (30 Gy). In case of PET-4 positive scan after 4 ABVD cycles (Deauville&#xD;
           score 4-5) patients will be planned to perform the biopsy and in case of positive&#xD;
           results, proceed to high-dose chemotherapy with autologous stem cell transplantation&#xD;
           (HDT with ASCT). In case of negative results of the biopsy, they will proceed with&#xD;
           additional 2 ABVD courses and restage again. Those with a PET-6 negative scan (Deauville&#xD;
           Score 1-3) will proceed with radiotherapy on initially involved site (30 Gy). In case of&#xD;
           PET-6 positive scan (Deauville score 4-5) patients will be proceeded to HDT with ASCT.&#xD;
&#xD;
           Those with a PET-2 Deauville score 5 after 2 ABVD courses will be planned to perform the&#xD;
           biopsy and in case of positive results, proceed to HDT with ASCT. In case of negative&#xD;
           results of the biopsy they will proceed with additional 2 ABVD courses and restage&#xD;
           again. Those with a PET-4 negative scan (Deauville Score 1-3) will proceed with&#xD;
           radiotherapy on initially involved site (30 Gy). In case of PET-4 positive scan&#xD;
           (Deauville score 4-5) patients will be proceeded to HDT with ASCT.&#xD;
&#xD;
        2. Early unfavorable (stages IA-B, IIA bulky and/or extranodal lesions, patients younger 50&#xD;
           years). Patients will receive two courses of EACODD-14 (etoposide 100 mg/m2 days 1-3,&#xD;
           doxorubicin 50 mg/m2 day 1, cyclophosphamide 650 mg/m2 day 1, vincristine 1,4 mg/m2 day&#xD;
           8, dacarbazine 375 mg/m2 day 1, dexamethasone 20 mg days 1-3; cycle is repeated every 14&#xD;
           days). Those with a PET-2 negative scan (Deauville Score 1-3) will be deescalated to 2&#xD;
           courses of AVD (Adriamycin, vinblastine, and dacarbazine) and consolidative radiotherapy&#xD;
           on initially involved site (30 Gy). Those with a PET-2-positive scan (Deauville score&#xD;
           4-5) will proceed with additional 2 EACODD-14 courses. After that, those with a PET-4&#xD;
           negative scan (Deauville Score 1-3) will proceed with radiotherapy on initially involved&#xD;
           site (30 Gy). In case of PET-4 positive scan after 4 EACODD-14 cycles (Deauville score&#xD;
           4-5) patients will proceed with additional 2 EACODD-14 courses. After that, those with a&#xD;
           PET-6 negative scan (Deauville Score 1-3) will proceed with radiotherapy on initially&#xD;
           involved site (30 Gy). In case of PET-6 positive scan (Deauville score 4-5) patients&#xD;
           will be proceeded to HDT with ASCT.&#xD;
&#xD;
        3. Advanced stages (younger 50 years). Patients will receive two courses of EACODD-14.&#xD;
           Those with a PET-2 negative scan (Deauville Score 1-3) will proceed with 4 additional&#xD;
           courses of EACODD-14. After that, patients with residual tumor ˂ 4 cm, will stop the&#xD;
           therapy and start the follow-up phase. Patients with residual tumor ≥ 4 cm, will undergo&#xD;
           consolidative radiotherapy on residual tumor (30 Gy). Those with a PET-2-positive scan&#xD;
           (Deauville score 4-5) will proceed with additional 4 additional courses of EACODD-14.&#xD;
           After that, those with a PET-6 negative scan (Deauville Score 1-3) will proceed with&#xD;
           radiotherapy on residual tumor ≥ 2,5 cm (30 Gy). In case of PET-6 positive scan&#xD;
           (Deauville score 4-5) patients will be proceeded to HDT with ASCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate (CR)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>CR rate is defined as the proportion of patients achieving a CR after 3 months of chemotherapy (interim) and at the end of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>The severity of the toxicities will be classified according to definitions of Common Terminology Criteria for Adverse Event (CTCAE) version 4.3. It will be determined by the incidence of severe, life- threatening (CTCAE grade 3, 4 and 5) and/or serious adverse events (Infusion-related reactions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Late Toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>The severity of the toxicities will be classified according to definitions of Common Terminology Criteria for Adverse Event (CTCAE) version 4.3. It will be determined by the incidence of severe, life- threatening (CTCAE grade 3, 4 and 5) and/or serious adverse events (Infusion-related reactions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>EFS will be measured from the time from entry onto a study to any treatment failure including disease progression, or discontinuation of treatment for any reason (e.g., disease progression, toxicity, patient preference, initiation of new treatment lacking documented progression, or death)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>DFS will be measured from the time of occurrence of disease-free state or attainment of a CR to disease recurrence or death as a result of lymphoma or acute toxicity of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>OS is defined as the time from entry onto the clinical trial until death as a result of any cause</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hodgkin Lymphoma, Adult</condition>
  <arm_group>
    <arm_group_label>Early favorable HL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL without adverse prognostic factors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early unfavorable HL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early unfavorable (stages IA-B, IIA bulky and/or extranodal lesions, age less than 50 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced stages HL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(age less than 50 years)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>25 mg/m2 i.v. day 1,15 for ABVD/AVD</description>
    <arm_group_label>Early favorable HL</arm_group_label>
    <arm_group_label>Early unfavorable HL</arm_group_label>
    <other_name>ABVD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>10,000 units/m2 i.v. days 1,15 for ABVD</description>
    <arm_group_label>Early favorable HL</arm_group_label>
    <other_name>ABVD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>6 mg/m2 i.v. days 1,15 for ABVD/AVD</description>
    <arm_group_label>Early favorable HL</arm_group_label>
    <arm_group_label>Early unfavorable HL</arm_group_label>
    <other_name>ABVD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>375 mg/m2 i.v. days 1,15 for ABVD/AVD</description>
    <arm_group_label>Early favorable HL</arm_group_label>
    <arm_group_label>Early unfavorable HL</arm_group_label>
    <other_name>ABVD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>100 mg/m2 i.v. days 1-3</description>
    <arm_group_label>Advanced stages HL</arm_group_label>
    <arm_group_label>Early unfavorable HL</arm_group_label>
    <other_name>EACODD-14</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m2 i.v. day 1 for EACODD-14</description>
    <arm_group_label>Advanced stages HL</arm_group_label>
    <arm_group_label>Early unfavorable HL</arm_group_label>
    <other_name>EACODD-14</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>650 mg/m2 i.v. day 1</description>
    <arm_group_label>Advanced stages HL</arm_group_label>
    <arm_group_label>Early unfavorable HL</arm_group_label>
    <other_name>EACODD-14</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1,4 mg/m2 i.v. day 8</description>
    <arm_group_label>Advanced stages HL</arm_group_label>
    <arm_group_label>Early unfavorable HL</arm_group_label>
    <other_name>EACODD-14</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20 mg i.v. days 1-3</description>
    <arm_group_label>Advanced stages HL</arm_group_label>
    <arm_group_label>Early unfavorable HL</arm_group_label>
    <other_name>EACODD-14</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>375 mg/m2 i.v. day 1 for EACODD-14</description>
    <arm_group_label>Advanced stages HL</arm_group_label>
    <arm_group_label>Early unfavorable HL</arm_group_label>
    <other_name>EACODD-14</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed classical HL&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
          -  Age 18-5 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2&#xD;
&#xD;
          -  Adequate organ and marrow function as defined below: absolute neutrophil count &gt;1,0&#xD;
             x109/L, platelets &gt;75 x109/L&#xD;
&#xD;
          -  Total bilirubin &lt;2 mg/dl without a pattern consistent with Gilbert's syndrome&#xD;
&#xD;
          -  Creatinine within normal institutional limits or creatinine clearance &gt;50 mL/min/1.73&#xD;
             m2&#xD;
&#xD;
          -  Females of childbearing must have a negative pregnancy test at medical supervision&#xD;
             even if had been using effective contraception&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          -  Sign (or their legally acceptable representatives must sign) an informed consent&#xD;
             document indicating that they understand the purpose of and procedures required for&#xD;
             the study and are willing to participate in the study.&#xD;
&#xD;
          -  Access to PET-CT (positron emission computed tomography) scans facilities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nodular Lymphocyte Predominant HL&#xD;
&#xD;
          -  Prior chemotherapy or radiation therapy&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Cardiac arrhythmia, conduction abnormalities, ischemic cardiopathy, left ventricular&#xD;
             hypertrophy or left ventricular ejection fraction (LVEF) ≤50% at echocardiography.&#xD;
&#xD;
          -  Abnormal QTc (corrected QT interval) interval prolonged (&gt;450 msec in males; &gt;470 msec&#xD;
             in women)&#xD;
&#xD;
          -  Uncontrolled infectious disease&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positivity or active infectious A, B or C&#xD;
             hepatitis. HBsAg-negative patients with anti-HBc (hepatitis B core antigen) antibody&#xD;
             and can be enrolled provided that Hepatitis B Virus (HBV)-DNA are negative and that&#xD;
             antiviral treatment with nucleos(t)ide analogs is provided&#xD;
&#xD;
          -  Uncompensated diabetes&#xD;
&#xD;
          -  Refusal of adequate contraception&#xD;
&#xD;
          -  Any medical or psychiatric illness that could, in the investigator's opinion,&#xD;
             potentially interfere with the completion of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladislav Sarzhevskiy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladislav Sarzhevskiy, PhD</last_name>
    <phone>+79104360040</phone>
    <email>vladsar100@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikita Mochkin, PhD</last_name>
    <phone>+79104568706</phone>
    <email>nickmed@yandex.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladislav Sarzhevskiy, MD, PhD</last_name>
      <phone>+74956037217</phone>
      <email>vladsar100@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nikita Mochkin, MD, PhD</last_name>
      <phone>+74956037217</phone>
      <email>nickmed@yandex.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EACODD-14</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

